


CURRICULUM VITAE FOR ACADEMIC PROMOTION
The Johns Hopkins University School of Medicine

(Signature): 

Channing J. Paller

1/24/2017
Date

DEMOGRAPHIC AND PERSONAL INFORMATION

Current Appointments

- 07/12 – Present Assistant Professor of Oncology, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
- 07/12 – Present Assistant Professor of Oncology, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital, Washington, DC
- 12/12 – Present Faculty Director, Specimen Accessioning Core, Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital, Washington, DC
- 06/15 – Present Co-Director, Sibley Prostate Cancer Multidisciplinary Clinic, Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital, Washington, DC
- 01/16 – Present Director, Medical Oncology Fellowship Clinical Rotation Education Program

Hospital Appointments

- 07/12 – Present Sibley Memorial Hospital, Washington, DC

Education and Training

Undergraduate

- 2001 A.B., Biochemistry and Neuroscience, Bowdoin College, Brunswick, ME

Doctoral/graduate

- 2005 M.D., Harvard Medical School, Boston, MA

Postdoctoral

- 2005 – 2006 Intern, Johns Hopkins University, Baltimore, MD
- 2006 – 2008 Resident, Johns Hopkins University, Baltimore, MD
- 2008 – 2009 Hematology Fellow, Johns Hopkins University, Baltimore, MD
- 2009 – 2012 Oncology Fellow, Johns Hopkins University, Baltimore, MD

Professional Experience

- 2012 – Present Assistant Professor, Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
- 2012 – Present Assistant Professor, Oncology, Sibley Memorial Hospital, Washington, DC
- 2012 – Present Faculty Director, Specimen Accessioning Core, Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital, Washington, DC

RESEARCH ACTIVITIES

Peer-Reviewed Original Science Research Publications

1. Somjen, D., Paller, C., Gayer, B., Kohen, F., Knoll, E. and Stern, N. High glucose blocks estradiol's effects on human vascular cell growth: differential interaction with estradiol and raloxifene. *Journal of Steroid Biochemistry and Molecular Biology*, 2004, 88:101-110. PMID: 3638755.

2. **Paller C.**, Shiels M., Rohrmann S., Basaria S., Rifai N., Nelson W., Platz E., Dobs A. Relationship of sex steroid hormones with bone mineral density (BMD) in a nationally rePresentative sample of men. *Clin Endocrinol (Oxf)*. 2008, 70(1):26-34. PMID: PMC3494466
3. **Paller CJ**, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, Stockton BR, Hertzman BL, Efros MD, Roper RP, Liker HR, Carducci MA. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. *Prostate Cancer Prostatic Dis*. 2013 Mar;16(1):50-5. doi: 10.1038/pcan.2012.20. Epub 2012 Jun 12. PMID: PMC3549301.
4. **Paller, C.**, Shiels, M., Rohrmann, S., Menke, A., Rifai, N., Nelson, W., Platz, E., Dobs, A. Association between Sex Steroid Hormones and Hematocrit in a Nationally-RePresentative Sample of Men. *J of Andrology*. 2012 Nov-Dec; 33(6): 1332-41. PMID: PMC3774012.
5. **Paller CJ**, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. *Clin Adv Hematol Oncol*. 2013 Jan;11(1):14-23. PMID: PMC3624708.
6. **Paller, C.**, Ye, X, Wozniak, P., Gillespie, B., Sieber, P., Greengold, R., Stockton, B., Hertzman, B., Efros, M., Roper, R., Liker, H., Carducci, M. A phase II study of pomegranate extract for men with rising prostate specific antigen following primary therapy. *Prostate Cancer and Prostatic Diseases*. 2013 Mar; 16(1):50-5. PMID: PMC3549301.
7. **Paller CJ**, Olatoye D, Xie S, Zhou X, Denmeade SR, Eisenberger MA, Antonarakis ES, Carducci MA, Rosner GL. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer. *Prostate Cancer Prostatic Dis*. 2014 Mar;17(1):28-33. doi: 10.1038/pcan.2013.40. Epub 2013 Oct 8. PMID: PMC3945997.
8. **Paller, C.**, Olatoye, D., Xie, S., Zhou, X., Denmeade, S.R., Eisenberger, M.A., Antonarakis, E.S., Carducci, M.A., Rosner, G.L. The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer. *Prostate Cancer and Prostatic Diseases*. 2014 June; 17(2):28-33. PMID: PMC3945997.
9. Antonarakis ES, Lu C, Wang H, Lubner B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, **Paller CJ**, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. *N Engl J Med*. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3. PMID: PMC4201502.
10. Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, **Paller CJ**, Carducci MA, Eisenberger MA, Antonarakis ES. Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. *Prostate*. 2014 Nov;74(15):1560-8. PMID: PMC4176523.
11. **Paller, C.**, Wissing, M., Mendonca, J., Kim, E., Kortenhorst, M., Gerber, S., Rosen, M., Shaikh, F., Zahurak, M., Rudek, M., Hammers, H., Rudin, C., Carducci, M., Kachhap, S. Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances anti-tumor activity in prostate cancer in vitro and in vivo. *Cancer Med*. 2014 Oct;3(5):1322-35. PMID: PMC4302682.
12. **Paller CJ**, Kanaan YM, Beyene DA, Naab TJ, Copeland RL, Tsai HL, Kanarek NF, Hudson TS. Risk of Prostate Cancer in African American Men: Evidence of Mixed Effects of Dietary Quercetin by Serum Vitamin D Status. *Prostate*. 2015 Sep;75(13):1376-83. PMID: PMC4536082.
13. **Paller CJ**, Rudek MA, Zhou XC, Wagner WD, Hudson TS, Anders N, Hammers HJ, Dowling D, King S, Antonarakis ES, Drake CG, Eisenberger MA, Denmeade SR, Rosner GL, Carducci MA. A Phase I Study of Muscadine Grape Skin Extract in Men with Biochemically Recurrent Prostate Cancer: Safety, Tolerability, and Dose Determination. *Prostate*. 2015 Oct;75(14):1518-25. PMID: NIHMS689473.
14. Antonarakis ES, Changxue Lu, Brandon Lubner, Hao Wang, Yan Chen, Mary Nakazawa, Nadal R, **Paller CJ**, Denmeade SR, Carducci MA, Eisenberger MA, Jun Luo. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. *JAMA Oncology*. 2015 Aug;1(5):582-91. PMID: PMC4537351.
15. Markowski M, Eisenberger M, Zahurak M, Epstein JI, and **Paller CJ**. Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series from Johns Hopkins Hospital. *Urology*. 2015 Sep;86(3):539-43. PMID: PMC456951.
16. Nakazawa M, Lu C, Chen Y, **Paller CJ**, Carducci MA, Eisenberger MA, Luo J, Antonarakis ES. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. *Ann Oncol*. 2015 Sep;26(9):1859-65. PMID: PMC4551160.
17. Nadal R, Tsai HL, Sinibaldi VJ, **Paller CJ**, Antonarakis ES, Denmeade SR, Carducci MA, Eisenberger MA. Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer

- treated with sequential novel androgen receptor-directed therapies. *Prostate*. 2016 Apr;76(5):512-20. doi: 10.1002/pros.23141. Epub 2015 Dec 22.
18. Schweizer MT, Wang H, Lubner B, Nadal R, Spitz A, Rosen DM, Cao H, Antonarakis ES, Eisenberger MA, Carducci MA, **Paller C**, Denmeade SR. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study. *Prostate*. 2016 Sep;76(13):1218-26. PMID: 27338150
 19. Ball MW, Gorin MA, Guner G, Pierorazio PM, Netto G, **Paller CJ**, Hammers HJ, Diaz LA, Allaf ME. Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study. *Clin Genitourin Cancer*. 2016 Oct;14(5):e515-e520. PMID: PMC5035558
 20. Goldstein A, Valda Toro P, Lee J, Silberstein JL, Nakazawa M, Waters I, Cravero K, Chu D, Cochran RL, Kim M, Shinn D, Torquato S, Hughes RM, Pallavajjala A, Carducci MA, **Paller CJ**, Denmeade SR, Kressel B, Trock BJ, Eisenberger MA, Antonarakis ES, Park BH, Hurley PJ. Detection fidelity of AR mutations in plasma derived cell-free DNA. *Oncotarget*. 2017 Jan 31. doi: 10.18632/oncotarget.14926. [Epub ahead of print] PMID:28152506
 21. Maughan BL, Suzman DL, Lubner B, Wang H, Glavaris S, Hughes R, Sullivan R, Harb R, Boudadi K, **Paller C**, Eisenberger M, Demarzo A, Ross A, Antonarakis ES. Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer. *Cancer Chemother Pharmacol*. 2016 Dec;78(6):1297-1304. PMID:27826729

Inventions, Patents, Copyrights

3/30/12 Paller CJ, Carducci M, Kachhap S. Patent submission: USE OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL-2-THIENYL)-1-PHTHALAZINAMINE IN COMBINATION WITH HISTONE DEACETYLASE INHIBITORS FOR TREATMENT OF CANCER

Extramural Funding

Current

03/08/16 – 03/01/19 The role of TGF-beta inhibition in overcoming drug resistance in metastatic castration resistant prostate cancer
Grant: K23CA197526-01A1
National Institutes of Health
\$164,000
Role: PI, 75%

Pending

09/01/16 – 08/31/19 Supporting Cancer Genomics Projects with the Bionimbus Protected Data Cloud.
National Institutes of Health – U24
\$50,000, Robert Grossman, University of Chicago, is PI
Role: Co-Investigator, 3%

Previous

7/01/09 – 6/30/11 Investigating the effects of HDACIs and other agents with spindle checkpoint inhibitors (Aurora kinase inhibitor AMG900 and PLK1 inhibitors BI2536 and BI6727) in combination in lung cancer and prostate cancer cell lines
5T32CA009071
NIH
\$472,728
PI: Nelson W
Role: Trainee

7/01/13 – 6/30/14 Race as a risk factor for metastatic prostate cancer: a sentinel event series

FH B33 CRF
Maryland Cigarette Restitution Fund
\$50,000
Role: PI, 25%

Research Program Building/Leadership

12/12 – Present Faculty Director, Specimen Accessioning Core, Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital, Washington, DC

EDUCATIONAL ACTIVITIES

Educational Publications

Peer-Reviewed, Original, Educational Publications

1. **Paller, C.**, Bradbury, P.A., Ivy, P., Seymour, L., LoRusso, P., Baker, L., Rubinstein, L., Huang, E., Collyar, D., Groshen, S., Reeves, S., Ellis, L.M., Sargent, D., Rosner, G.L., LeBlanc, M., Ratain, M.J. The Design of Phase 1 Combination Trials: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. *Clinical Cancer Research*. 2014, 20(16): 4210–4217. PMID: PMC4135521.
2. van Die MD, Bone KM, Emery J, Williams SG, Pirota MV, **Paller CJ**. Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trials. *BJU Int*. 2016 Feb 22.
3. Nakazawa M, **Paller C**, Kyprianou N. Mechanisms of Therapeutic Resistance in Prostate Cancer. *Curr Oncol Rep*. 2017 Feb;19(2):13. doi: 10.1007/s11912-017-0568-7.

Invited Review Articles

1. **Paller C**, Campbell C, Edwards R, Dobs A. Sex-based differences in pain perception and treatment. *Pain Medicine*. 2009, 10(2):289-299. PMID: PMC2745644.
2. **Paller C**, Antonarakis E. Cabazitaxel: a second-line treatment for metastatic castration-resistant prostate cancer. *Drug Des Devel Ther*. 2011 Mar 10;5:117-24. PMID: PMC3063116.
3. **Paller C**, Antonarakis E. Sipuleucel-T for the treatment of prostate cancer: the promise and the challenge. *Human Vaccines*. 2012 Apr;8(4):509-19. PMID: PMC22336881.
4. **Paller C**, Carducci M, Philips G. Management of Bone Metastases in Refractory Prostate Cancer - Role of Denosumab. *Journal Clinical Interventions in Aging*. 2012; 7:363–372. PMID: PMC3459574.
5. **Paller C**, Antonarakis A. Management of biochemically-recurrent prostate cancer after local therapy: evolving standards of care and new directions. *Clinical Advances in Hematology & Oncology*: 2013 Jan; 11(1):14-23. PMID: PMC3624708.
6. **Paller C**, Antonarakis E, Eisenberger M, Carducci M. Management of patients with biochemical recurrence after local therapy for prostate cancer. *Hematology/Oncology Clinics of North America*; 2013 Dec; 27(6):1205-19. PMID: PMC3818691.
7. **Paller C**, Denmeade S, Carducci M. Challenges of Conducting Clinical Trials of Natural Products in Cancer. *Clinical Advances in Hematology & Oncology*. Submitted in 2/2016.
8. Paller CJ, Denmeade SR, Carducci MA. Challenges of conducting clinical trials of natural products to combat cancer. *Clin Adv Hematol Oncol*. 2016 Jun;14(6):447-55. Review. PMID: 27379814
9. **Paller C**, Pantuck A, Carducci M. Pomegranate in Prostate Cancer: A Review, PCAN Accepted 2/22/2017.

Editorials

1. **Paller, C.** and Rudin, C. Youth has no age: cancer treatment for older Americans. *Oncology*. 2010 Nov 15;24(12):1114, 1118, 1120. PMID: PMC3482117.
2. **Paller, C.** and Smith, T. Finasteride and Prostate Cancer: A Commentary. *Oncologist*. 2012;17(7):888-90. Epub 2012 Jun 20. PMID: PMC3399642.

Case Reports

1. Rowe SP, Deville C, **Paller CJ**, Cho SY, Fishman EK, Pomper MJ, Ross AE, Gorin MA, “Uptake of 18F-DCFPyL in Paget’s Disease of Bone, an Important Potential Pitfall in Clinical Interpretation of PSMA PET Studies,” *Tomography*, 2015 Dec;1(2):81-84.
2. Markowski M, Imus P, Wright J, Schottenstein D, **Paller C**. Long term control of oligometastatic prostate cancer following stereotactic radiation therapy in the absence of ADT: A Case report. *Clinical Genitourinary Cancer*, Accepted 2/20/17.
3. Rowe SP, Deville C, **Paller C**, Cho SY, Fishman EK, Pomper MG, Ross AE, Gorin MA. Uptake of 18F-DCFPyL in Pagets Disease of Bone, an Important Potential Pitfall in Clinical Interpretation of PSMA PET Studies. *Tomography*. 2015 Dec;1(2):81-84.

Book Chapters

1. Movsas, B., Brahmer, J., **Paller, C.**, and Kernstine, K. Non-small-cell lung cancer in 13th Edition of *Cancer Management Handbook: A Multidisciplinary Approach Medical, Surgical & Radiation Oncology* (Pazdur, R., Camphausen, K., Hoskins, W., Wagman, L., Eds.) UBM Medica, London. 2010-2011.
2. Movsas, B., Brahmer, J., **Paller, C.**, and Kernstine, K. Non-small-cell lung cancer in 14th Edition of *Cancer Management Handbook: A Multidisciplinary Approach Medical, Surgical & Radiation Oncology* (Pazdur, R., Camphausen, K., Hoskins, W., Wagman, L., Eds.) UBM Medica, London. 2012.
3. **Paller, C.**, Smith, T. Strategies Addressing Quality of Life: Patient Reported Outcomes and Symptoms Management in Management of Castration Resistant Prostate Cancer (Saad, F., Eisenberger, M., Eds.) Springer Dordrecht Heidelberg London New York, 2014.

Teaching

Classroom Instruction

2010-2014 Spring or Fall, Small Group Courses: Palliative and End of Life Care Intersession “Genes to Society,” Small group leader (20-30 medical students), Johns Hopkins University School of Medicine, Baltimore, MD

Clinical Instruction

2015- present Residents and Fellows attending MultiDisciplinary Prostate Clinic

1/2016- present Medical Oncology Education Director for rotating medical oncology fellows (NIH, Howard, Hopkins)

CME Instruction

04/15 “Prostate Cancer Survivorship: Improving Outcomes, Enhancing Care,” Cancer Survivorship Symposium, (CME), Johns Hopkins Hospital, Baltimore, MD.

07/15 NCCN Sponsored Grand Rounds, “Caring for Patients with Castrate Resistant Prostate Cancer: Redefining Roles of Urologists and Oncologists,” Hampton VA Medical Center, Hampton, VA.

4/16 Keynote: “Integrated Care for Cancer Patients”, 12th International VHL Symposium, Massachusetts General Hospital, Boston, MA.

Workshops/Seminars

05/10 Southeastern Fellows Research Skills Retreat, Invited Participant, Duck, NC

08/10 AACR Vail Methods in Clinical Cancer Research Workshop, Invited Participant, Vail, CO

05/12 Molecular and Translational Oncology Workshop, Invited Participant, Fort Myers, FL

10/12 Merrill J. Egorin Workshop in Cancer Pharmacology, Invited Participant, Leesburg, VA

10/12 19th Annual Scientific Retreat of the Prostate Cancer Foundation, Invited Participant, Carlsbad, CA

03/13 Multi-Institutional Prostate Cancer Program Retreat, Invited Participant, Ft. Lauderdale, FL

10/13 20th Annual Scientific Retreat of the Prostate Cancer Foundation, Invited Participant, National Harbor, MD

10/13 Ninth International Workshop on Anti-Cancer Agents, Invited Participant, Northumberland, UK

10/14 21st Annual Scientific Retreat of the Prostate Cancer Foundation, Invited Participant, National Harbor, MD

10/15 22nd Annual Scientific Retreat of the Prostate Cancer Foundation, Invited Participant, National Harbor, MD

Mentoring

Advisees

2011 Faraz Shaikh, Medical Student, currently Resident in Internal Medicine, Wake Forest School of Medicine, Raleigh, NC Eastern Virginia Medical School

2011 Dare Olatoye, Medical Student, Johns Hopkins University, Baltimore, MD, currently resident in internal medicine, Mayo Clinic, Rochester, MN

2011- 2012 Sherlly Xie, Masters Student of Biostatistics, Johns Hopkins University, Baltimore, MD currently staff statistician, Medical College of New Jersey, Newark, NJ

2012- Present Mark Markowski, Oncology Fellow, Johns Hopkins University, Baltimore, MD

2012 Alex Cole, M.D. 2014, Johns Hopkins University School of Medicine, Baltimore, MD, currently clinical resident in urology, Brigham & Women's, Harvard Medical School, Boston, MA

2013 Francesca Courtinho, MPH (2014), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD Currently postdoctoral position in Canada

2014 Summer Savannah Windham, undergraduate at University of Wisconsin, Madison WI

2014- Present Laura Hendricks Jackson, Registered Nurse, DNP Candidate, Drexel and Hopkins Student, Baltimore, MD.

2015- Present Thomas Luechtefeld, Hopkins PhD Candidate

2016- Present Hogan Tang, PhD Research Associate, Bloomberg School of Public Health

2016- Present Jianqiang Lin, Associate Professor, GW

2016- Present Valerie Lee, Assistant Professor, Johns Hopkins

Thesis Committees

2016 Thomas Luechtefeld
2016 Laura Hendricks Jackson

Training Grant Participation

None

Educational Program Building / Leadership

Sibley Oncology Fellowship Program for Howard and NIH Fellows

Educational Extramural Funding

None

CLINICAL ACTIVITIES

Certification

Medical, other state/government licensure

2008-Present Maryland Medical License # D0067713

2008-Present Maryland Controlled Substances Registration # M65874

2008-Present United States Drug Enforcement Agency Registration #FP1047073

2013-Present District of Columbia Medical License # MD040576

Boards, other specialty certifications

2008 National Board of Medical Examiners

2008 American Board of Internal Medicine - Internal Medicine

2011 American Board of Internal Medicine - Oncology

Clinical (Service) Responsibilities

- 2012 – Present Prostate Cancer Multidisciplinary Clinic, Assistant Professor, monthly staffing/weekly participation, Baltimore and Washington, DC sites.
- 2012 – Present Sidney Kimmel Comprehensive Cancer Center / Sibley Memorial Hospital, Outpatient Clinic, 1.5 days/week

Investigational New Drug Applications

- 3/12 Muscadine Plus (MPX) In Men Following Initial Therapy For Prostate Cancer. IND 109605. Approved to proceed on 3/8/2012. Michael Carducci Sponsor.
- 3/15 Overcoming drug resistance in metastatic castration-resistant prostate cancer with novel combination of TGF- β receptor inhibitor LY2157299 and enzalutamide: a randomized multi-site phase II study. IND 125694. Approved to proceed on 3/3/15.
- 6/15 A Randomized Phase 2 Trial of Ascorbic Acid in Combination with Docetaxel in Men with Metastatic Prostate Cancer. IND 126543. Approved to proceed on 6/3/15.
- 12/15 IV Mistletoe Extract in Patients with Advanced Solid Tumors. IND 128726. Luis Diaz Sponsor.

Clinical Protocols

- 4/11 Phase I/II Study Of Safety And Efficacy Of Muscadine Plus (MPX) In Men With Prostate Cancer: A Randomized Dose-Finding Study Of The Effects Of Two Doses Of MPX Capsules On Rising Prostate-Specific Antigen Levels In Men Following Initial Therapy For Prostate Cancer. Protocol J1161. Investigator Initiated. Approved by JHU Clinical Research Review Committee.
- 1/13 Retrospective Review of Sarcomatoid Carcinoma of the Prostate. Protocol Z1279. Investigator Initiated. Approved by JHU Clinical Research Review Committee.
- 10/13 Race as a Risk Factor for Metastatic Prostate Cancer: A Sentinel Event Case Series. Protocol J1336. Investigator Initiated. Approved by JHU Clinical Research Review Committee.
- 1/15 Personalized medicine research trial: tissue analysis, biospecimen collection, whole-genome sequencing and molecular pathological analyses of a single patient to provide a deeper understanding of prostate cancer. Protocol J14169. Investigator Initiated. Approved by JHU Clinical Research Review Committee.
- 6/15 Overcoming drug resistance in metastatic castration-resistant prostate cancer with novel combination of TGF- β receptor inhibitor LY2157299 and enzalutamide: a randomized multi-site phase II study. Protocol J1557. Investigator Initiated. Approved by JHU Clinical Research Review Committee.
- 10/15 A Randomized Phase 2 Trial of Ascorbic Acid in Combination with Docetaxel in Men with Metastatic Prostate Cancer. Protocol J15106. Investigator Initiated. Approved by JHU Clinical Research Review Committee.
- 12/15 A Phase I Dose-Escalating Trial of Mistletoe Extract in Patients with Advanced Solid Tumors. Investigator Initiated.

Clinical Trials Open

- 7/13 A Phase III Randomized Trial Comparing Androgen Deprivation Therapy TAK-700 With Androgen Deprivation Therapy Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer.
Principal Investigator –Local, Hopkins multi-site.
Protocol S1216. ECOG Initiated. Approved by JHU Clinical Research Review Committee.
- 12/13 Race as a Risk Factor for Metastatic Prostate Cancer: A Sentinel Event Case Series.
Principal Investigator. Local, Hopkins multi-site.
Protocol J1336. Investigator Initiated. Approved by JHU Clinical Research Review Committee.
- 6/14 Immune Evaluation Study of Sipuleucel-T in African American and non-African American Men with Castrate Resistant Prostate Cancer.
Principal Investigator –Local, Hopkins multi-site.
Protocol 2013-108. Karmanos Initiated. Approved by JHU Clinical Research Review Committee.
- 4/15 Personalized medicine research trial: tissue analysis, biospecimen collection, whole-genome sequencing and molecular pathological analyses of a single patient to provide a deeper understanding of prostate cancer.
Principal Investigator, Local.
Protocol J14169. Investigator Initiated. Approved by JHU Clinical Research Review Committee.
- 1/16 Overcoming drug resistance in metastatic castration-resistant prostate cancer with novel combination of TGF- β receptor inhibitor LY2157299 and enzalutamide: a randomized multi-site phase II study.
Principal Investigator – National, 3 Sites
Protocol J1557. Investigator Initiated. Approved by JHU Clinical Research Review Committee.
- 2/16 A Randomized Phase 2 Trial of Ascorbic Acid in Combination with Docetaxel in Men with Metastatic Prostate Cancer.
Principal Investigator – National, 3 Sites.
Protocol J15106. Investigator Initiated. Approved by JHU Clinical Research Review Committee.
- 3/2017 IV Mistletoe Extract in Patients with Advanced Solid Tumors. Principal Investigator.
Protocol J1681, Investigator Initiated. Approved by JHU Clinical Research Review Committee.

Clinical Trials Completed

- 7/11 Phase I/II Study Of Safety And Efficacy Of Muscadine Plus (MPX) In Men With Prostate Cancer: A Randomized Dose-Finding Study Of The Effects Of Two Doses Of MPX Capsules On Rising Prostate-Specific Antigen Levels In Men Following Initial Therapy For Prostate Cancer.
Principal Investigator – National, 6 Sites
Protocol J1161. Investigator Initiated. Approved by JHU Clinical Research Review Committee.
- 1/16 A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features.
Principal Investigator –Local, Hopkins multi-site
Protocol E1808. ECOG Initiated. Approved by JHU Clinical Research Review Committee.
- 10/16 Phase I/II Study Of Safety And Efficacy Of Muscadine Plus (MPX) In Men With Prostate Cancer: A Randomized Dose-Finding Study Of The Effects Of Two Doses Of MPX Capsules On Rising Prostate-Specific Antigen Levels In Men Following Initial Therapy For Prostate Cancer.

Clinical Program Building/Leadership

06/15 – Present Co-Director, Sibley Prostate Cancer Multidisciplinary Clinic, Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital, Washington, DC

Clinical Extramural Funding (current, pending, previous)

Current

07/01/15-06/30/18 Non-invasive detection of AR-FL/AR-V7 as a predictive biomarker for therapeutic resistance in men with metastatic castration-resistant prostate cancer
PC141019
DOD/CDMRP
\$1,049,250
Role: Co-investigator, 5%

07/01/15-06/30/18 A Phase I Dose-Escalating Trial of Mistletoe Extract in Patients with Advanced Solid Tumors.
BelieveBig.Org
\$300,000
Role: PI, 1%

04/01/12 – 3/31/16 Muscadine Grape Skin Extract: Laboratory and Pilot Clinical Evaluation in Prostate Cancer: Phase I/II Trial
90050278
The Community Foundation for the National Capital Region
\$973,451
Role: PI, 1%

12/01/14 – 12/30/17 A Randomized Phase 2 Trial of Intravenous Ascorbate (Vitamin C) in Combination with Docetaxel in Men with Metastatic Castration Resistant Prostate Cancer
90061347
Billi Marcus Foundation
\$796,253
Role: PI, 4%

11/01/14 – 10/31/18 Overcoming drug resistance in metastatic castration resistant prostate cancer
15003789
The Community Foundation for the National Capital Region
\$884,956
Role: PI, 1%

5/01/14 – 4/30/17 Immune Evaluation Study of Sipuleucel-T in African American and European American Men with Castrate Resistant Prostate Cancer
2013-108
Dendreon Prime/ Karmanos Cancer Institute subcontract
\$10,000
Role: PI, 5%

02/16/16 – 02/15/18 Overcoming drug resistance in metastatic castration-resistant prostate cancer with novel combination of TGF-b receptor inhibitor LY2157299 and enzalutamide: a randomized multi-site phase II study
90066219
Lilly
\$249,999

Role: PI, 1%

Pending

Previous

01/01/15-3/01/16	Passano Physician Scientist Award for Phase II Trial of TGFB in mPCa Clinician Scientist Award Johns Hopkins University \$160,000 PI: 50%
03/01/15 – 02/20/16	Factors Affecting Combination Trial Success (FACTS) 5UM1CA186691 Supplement Cancer Therapy Evaluation Program (CTEP), NCI \$50,000 Role: PI, 12%
01/01/14 – 12/31/16	What Went Wrong: Eliminating Mistakes in Diagnosis and Treatment of Prostate Cancer 90057062 Start a Cure \$8,113 Role: PI, 1%
7/01/10 – 6/30/13	Investigator initiated Phase I/II Clinical Trial of MPX: FDA-required safety studies and correlative analyses Grant number N/A Community Foundation for the National Capital Region \$260,000 Role: PI, 12%
1/01/11 – 12/31/12	Animal studies of AMG 900 in combination with histone deacetylase inhibitors for prostate cancer Grant number N/A Community Foundation for the National Capital Region \$50,000 Role: PI, 10%
7/01/11 – 6/30/12	Investigator initiated evaluation of muscadine grape skin powder as a novel antitumor agent in men with rising PSA after primary therapy for prostate cancer: Phase I/II study Grant number N/A Conquer Cancer Foundation \$50,000 Role: PI, 65%
7/01/11 – 6/30/12	Exploring MPX as a potential prevention agent in men with prostate cancer ECOG Paul Carbone (MD Fellowship Award) Grant number N/A \$25,000 Role: PI, 35%

SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES

System Innovation and Quality Improvement Publications

None

System Innovation and Quality Improvement efforts within JHM

2014 - Present Physician leader of Comprehensive Unit-Based Safety Program (CUSP) for Oncology Infusion and clinic at Sibley Memorial Hospital.

System Innovation and Quality Improvement efforts outside of JHM

5/13/15 – present President, Genitourinary Multidisciplinary DC Regional Oncology Program (www.gumdroptrials.org). Led development of public database and web site for physicians and patients to identify local clinical trials.

Production of guidelines and/or protocols

8/2014 “The Design of Phase 1 Combination Trials: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee.” Co-Author.

System Innovation and Quality Improvement Program Building/Leadership

2014-Present Development of Specimen Accessioning Core at Sibley Memorial Hospital for SKCCC

System Innovation and Quality Improvement Extramural Funding

None

Extramural Funding

None

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments

2012 - Present Faculty Director of Specimen Accessioning Core lab at Sibley Memorial Hospital

2015 - Present Co-Director, Sibley Prostate Cancer Multidisciplinary Clinic, Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital, Washington, DC

Editorial Activities

Editorial Board Appointments

2013- Present PDQ Cancer Complementary Alternative Medicine Editorial Board, NIH

Journal Peer Review Activities

06/10 Invited Reviewer, The Prostate
02/12 Invited Reviewer, Prostate Cancer and Prostatic Diseases
10/12 Invited Reviewer, Journal of Oncology
12/12 Invited Reviewer, Evidence Based Complementary and Alternative Medicine
02/13 Invited Reviewer, Cancer
04/13 Invited Reviewer, Expert Review of Endocrinology and Metabolism
04/13 Invited Reviewer, Clinical Genitourinary Cancer
05/13 Invited Reviewer, Cancer Epigenetics
06/13 Invited Reviewer, Prostate Cancer
10/13 Invited Reviewer, Prostate Cancer and Prostatic Diseases
10/13 Invited Reviewer, Molecules
07/14 Invited Reviewer, Annals of Oncology
11/14 Invited Reviewer, ASCO Educational Book expert panel
02/15 Invited Reviewer, British Journal of Urology
03/15 Invited Reviewer, The Prostate
05/15 Invited Reviewer, The Prostate

05/15 Invited Reviewer, Urology
 07/15 Invited Reviewer, Expert Opinion On Therapeutic Patents
 3/16 Invited Reviewer, The Prostate
 3/16 Invited Reviewer, Prostate Cancer and Prostatic Diseases
 3/16 Invited Reviewer, PLOS One
 8/16 Invited Reviewer, PLOS One
 8/16 Invited Reviewer, ONCO Target
 10/16 Invited Reviewer, BMC Complementary and Alternative Medicine
 1/17 Invited Reviewer, BMC Urology

Invited Grant Review

2016- Present Fund for Innovation in Cancer Informatics, Advisory Committee

Advisory Committees, Review Groups/Study Sections

2009 – 2010 Member, Provider Order Entry (POE) Committee, Johns Hopkins University
 2012 – Present Member, NCI/CTEP/IDB Longitudinal project for the Clinical Trial Design Task Force of the Investigational Drug Steering Committee (IDSC)
 2012 - Present Member, Faculty Selection Committee, Sibley Memorial Hospital

Professional Societies

2002 – 2004 Member, American College of Physicians
 2002 – 2004 Student Representative, Massachusetts Medical Society
 2009- Member, American Society of Clinical Oncology
 2010- Member, American Association for Cancer Research

Conference Organizer, Session Chair

5/31/15 ASCO 2015 Session co-Chair, Genitourinary (Prostate) Cancer. Oral Abstract Session
 10/08/15 Moderator, Ascorbic Acid in Prostate Cancer Treatment,” Prostate Cancer Foundation Annual Scientific Retreat, Washington, DC.

Consultantships

05/14 Sipulecel T, Dendreon

RECOGNITION

Awards, Honors

2011 Clinical Research Honorable Mention for Research Day, Sidney Kimmel Comprehensive Cancer Center
 2011 Merit Award to attend 2011 ASCO Annual Conference
 2011 – 2012 ASCO Conquer Cancer Foundation Young Investigators Award
 2011 – 2012 Paul Carbone ECOG Fellowship
 2012 Patients’ Choice Award from American Registry
 2012 Most Compassionate Doctor Award from American Registry
 2012 Merit Award to attend 2012 ASCO Annual Conference
 2015 Passano Clinician Scientist Award
 2016 NIH K23 Mentored Patient-Oriented Research Career Development Award

Invited Talks, Panels

09/21/11 Presenter, Bench to Bedside: Novel Approaches in treating prostate cancer, University Hospital Seidman Cancer Center, Cleveland, OH
 10/11/11 Presenter, “Bench to Bedside: Novel approaches in treating prostate cancer,” University of Michigan, Ann Arbor, MI
 10/25/11 Presenter, “Bench to Bedside: Novel approaches in treating prostate cancer”

- Barbara Ann Karmanos Cancer Center, Detroit, MI
- 10/27/11 Presenter, “Bench to Bedside: Novel approaches in treating prostate cancer”
UT Southwestern, Dallas, TX
- 11/01/11 Presenter, “Bench to Bedside: Novel approaches in treating prostate cancer”
Vanderbilt-Ingram Cancer Center, Nashville, TN
- 06/18/12 “Finding Suitable Trials as a Doctor Or A Patient In A User-Friendly, Intuitive Fashion”
Genitourinary Multi-disciplinary Regional Oncology Program, Washington, DC
- 07/17/13 Presenter, “Region-Wide Poster and Website For Informing Patients and Physicians About Suitable
GU-Oncology Clinical Trials,” Genitourinary Multi-disciplinary Regional Oncology Program,
Washington, DC
- 09/19/13 Presenter, “What Went Wrong: Eliminating Mistakes in Diagnosis and Treatment of Prostate
Cancer,” 9th Annual African American Prostate Cancer Disparity Summit, Washington, DC.
- 09/23/13 Presenter, “Knowledge is Power Rising PSA after Treatment for Prostate Cancer: The Treatment
Dilemma,” 8th Annual Prostate Cancer Symposium, Bethesda, MD.
- 10/23/13 Presenter, “Challenges of Natural Product Drug Development,” Translational Research Conference at
the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
- 04/16/14 Presenter, “Novel Therapies for Prostate Cancer,” George Washington University Hospital Grand
Rounds, Washington, DC.
- 04/30/14 Presenter, “What’s New in Prostate Cancer?” Suburban Hospital, Bethesda, MD.
- 06/13/14 Presenter, “Novel Therapies for Metastatic Prostate Cancer,” Harbor Hospital Grand Rounds,
Baltimore, MD.
- 04/17/15 Presenter, “Prostate Cancer Survivorship: Improving Outcomes, Enhancing Care,” Cancer
Survivorship Symposium, (CME), Johns Hopkins Hospital, Baltimore, MD.
- 04/20/15 Presenter, “Hereditary Risk and Prostate Cancer,” Suburban Hospital, Bethesda, MD
- 06/9/15 Presenter, “Prostate Cancer Survivorship: What Does It Mean For You?” Sibley Memorial Hospital
Knowledge Is Power Series, Washington, DC
- 06/19/15 Grand Rounds, “TKIs in Metastatic RCC: Treatment Choices in an Intricate Landscape,” Johns
Hopkins Kimmel Cancer Center Grand Rounds, Baltimore, MD.
- 07/01/15 Grand Rounds, “Caring for Patients with Castrate Resistant Prostate Cancer: Redefining Roles of
Urologists and Oncologists,” Hampton VA Medical Center, Hampton, VA.
- 10/8/15 Presentation, “Rigorous Assessment of IV Ascorbate in Combination with Docetaxel in mCRPC
Prostate Cancer,” Prostate Cancer Foundation Annual Scientific Retreat, Washington, DC.
- 3/2/16 Presentation, “FACTS: Factors Affecting Combination Trial Success.” NIH/CTEP, Rockville, MD.
- 3/9/16 Presentation, “Rigorous placebo-controlled clinical trial of ascorbate in combination with docetaxel in
CRPC.” Marcus Foundation Integrative Health Workshop, Thomas Jefferson University,
Philadelphia. PA.
- 4/5/16 Presentation: “Trends and Recent Developments in Cancer Research and Treatment”, Osher Lifelong
Learning Institute, Rockville, MD.
- 4/6/16 Presentation: “A randomized phase 2 trial of ascorbic acid in combination with Docetaxel in men
with metastatic prostate cancer”, International Cancer Study & Therapy Conference, Baltimore, MD.
- 4/8/16 Keynote: “Integrated Care for Cancer Patients”, 12th International VHL Symposium, Massachusetts
General Hospital, Boston, MA.
- 4/12/16 Presentation: “Is There a Clinical Trial In Your Future? How To Find the Right One”, Us Too:
International Prostate Cancer Education & Support Network, Fairfax-Falls Church, VA, Support
Group. Fairfax, VA.
- 5/11/16 Mistletoe and Cancer: Promises and Challenges, National Cancer Institute Strategic Workshop.
Bethesda, DC.
- 2/15/17 A Randomized Dose-Finding Placebo Controlled Phase II Study of Muscadine Grape Skin in Men
with Rising PSA following Local Therapy. PCCTC Meeting, GU-ASCO, Orlando, FL

OTHER PROFESSIONAL ACCOMPLISHMENTS

- 5/13/15 – present President, Genitourinary Multidisciplinary DC Regional Oncology Program
(www.gumdroptrials.org)

